Surgical oncology: Alternatives to surgery after failure of instillation therapy

Nature Reviews Clinical Oncology

Volumn 7, Issue 6, 2010, Pages 307-308

  Weiss, Christian ^a   Rödel, Claus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GEMCITABINE; MITOMYCIN;

ALTERNATIVE MEDICINE; BLADDER CANCER; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CYSTECTOMY; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; NON MUSCLE INVASIVE BLADDER CANCER; ORGAN PRESERVATION; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT CANCER; RISK ASSESSMENT; SHORT SURVEY; SURVIVAL RATE; THERAPY DELAY; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; INTRAVESICAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVESICAL; CYSTECTOMY; HUMANS;

EID: 77953153976     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.69     Document Type: Short Survey

References (10)

1. Parkin, D. M. The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. (suppl. 218), 12-20 (2008).
2. Kirkali, Z. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66, 4-34 (2005).
3. Babjuk, M. et al. eAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303-314 (2008).
4. Addeo, R. et al. Randomized phase iii trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J. Clin. Oncol. 28, 543-548 (2010).
5. Herr, H. w. & Dalbagni, G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J. Urol. 169, 1706-1708 (2003).
6. Dalbagni, G. et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérinrefractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 24, 2729-2734 (2006).
7. Rödel, C., weiss, C. & sauer, R. Trimodality treatment and selective organ preservation for bladder cancer. J. Clin. Oncol. 24, 5536-5544 (2006).
8. wo, J. Y. et al. The results of concurrent chemoradiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscleinvasive bladder cancer: is immediate cystectomy always necessary? BJU Int. 104, 179-183 (2009).
9. weiss, C. et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J. Clin. Oncol. 24, 2318-2324 (2006).
10. weiss, C. et al. Treatment options for high-risk T1 bladder cancer: status quo and future perspectives of radiochemotherapy. Strahlenther. Onkol. 184, 443-449 (2008).